ERBB2 and gastric adenocarcinoma: These findings highlight the importance of chemotherapy backbone in the first-line treatment of advanced oesophago-gastric adenocarcinoma in the absence of biomarkers beyond HER2 and PD-L1 expression, as we have also seen with HER2-negative disease [69].